LM-101 injection study for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and willing to sign consent before any study steps
- Your cancer is an advanced solid tumor that has returned or keeps growing after standard treatment
- You have at least one measurable tumor spot the doctors can track on scans
- You can do daily activities fairly well (ECOG 0–1) and are expected to live at least 3 months
- Your recent labs show your organs and bone marrow can handle treatment (checked within 7 days before the first dose)
- If you join the combination part, you must provide stored or fresh tumor tissue for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug called LM-299 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if LM-299 is safe and effective.
This study tests a new experimental drug, LM-364, given alone or with other cancer treatments for people with advanced solid tumors. It aims to see if the drug is safe and effective.
This early-phase study tests LM103 in people with advanced solid cancers that have not responded to standard treatments or where standard options are not suitable. It mainly focuses on whether LM103 can be safely given and whether it can shrink tumors or help control the disease.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
Hear when a new Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.